Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06985147 | A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV) | PHASE2 | RECRUITING | 60 | — | — | Aug 12, 2025 | Feb 1, 2029 | May 28, 2026 | 15 | United States |
Proportion of participants with treatment-emergent adverse events
Proportion of participants with changes in vital signs
Proportion of participants with changes in physical examinations
Proportion of participants with changes in electrocardiograms (ECGs)
Proportion of participants with changes in clinical laboratory results
| Arm | Type | Description |
|---|---|---|
| Within-participant dose escalation | EXPERIMENTAL | This is an open-label, multicenter, within-participant dose escalation study examining up to 2 dose levels of DISC-3405. |
| Name | Type | Description |
|---|---|---|
| DISC-3405 | DRUG | DISC-3405 is administered subcutaneously. |
Inclusion Criteria: 1. Aged 18 years or older at the time of signing the informed consent form (ICF). 2. Meet revised 2022 World Health Organization (WHO) criteria for the diagnosis of PV. 3. Complete blood count values at Screening of HCT \<45% or HCT \<48% if followed by a phlebotomy within 2 wee...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Protagonist Therapeutics, Inc. | PTGX | 2 | PHASE3 | Rusfertide, Open-label rusfertide |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| Ionis Pharmaceuticals, Inc. | IONS | 1 | PHASE2 | sapablursen |
| Disc Medicine, Inc. | IRON | 1 | PHASE2 | DISC-3405 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| Novartis AG Sponsored ADR | NVS | 1 | — | Undisclosed |